Previous Close | 151.13 |
Open | 151.48 |
Bid | 152.30 x 1000 |
Ask | 152.90 x 800 |
Day's Range | 150.83 - 152.76 |
52 Week Range | 150.11 - 186.69 |
Volume | |
Avg. Volume | 8,039,859 |
Market Cap | 399.1B |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | 26.97 |
EPS (TTM) | 5.66 |
Earnings Date | Apr 18, 2023 |
Forward Dividend & Yield | 4.52 (2.80%) |
Ex-Dividend Date | Feb 17, 2023 |
1y Target Est | 183.63 |
Pfizer's biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.
It’s not just TikTok as a company that has a lot at stake right now. The people who are on TikTok the most, the influencers — also called creators — are also in the crosshairs.